Nephrotoxicity — Kidney Damage from Cancer Treatments

Nephrotoxicity is defined as the poisonous or adverse effect of chemical substances, drugs, or environmental agents on renal structure and function. The kidneys are particularly susceptible to toxic injury because they receive approximately twenty percent of resting cardiac output and concentrate filtered toxins within the renal tubules and interstitium during the filtration process.

In the context of cancer treatment, nephrotoxicity can manifest in several distinct pathological patterns. These include acute tubular necrosis, interstitial nephritis, glomerular injury, or microvascular damage. It can lead to an abrupt decline in the glomerular filtration rate, electrolyte disturbances, impaired fluid regulation, and in severe instances, acute kidney injury or irreversible chronic kidney disease requiring long-term intervention.

Protecting kidney health is vital because healthy kidneys allow the body to process and clear cancer medications efficiently. If nephrotoxicity develops, drug levels can build up in the bloodstream, increasing the likelihood of other severe side effects. Furthermore, kidney impairment may force oncologists to pause therapy, lower drug doses, or switch to alternative treatments that might be less established. Proactive monitoring helps maintain both the effectiveness of cancer therapy and long-term renal health.

Kidney health is tracked using routine blood and urine biomarkers. Key blood tests include serum creatinine and blood urea nitrogen, alongside the estimated glomerular filtration rate. Urinalysis evaluates proteinuria, haematuria, or electrolyte wasting. When high-risk therapies are planned, more sensitive clearance tests or specialised protein markers, such as cystatin C, may be employed to assess kidney function with greater precision.

Nephrotoxicity can emerge during the treatment of many cancers. It frequently arises in patients receiving platinum-based chemotherapy for testicular, ovarian, lung, or head and neck cancers. It is also an important consideration in haematological malignancies such as multiple myeloma, acute leukaemia, and lymphoma, where both disease-related proteins and therapeutic regimens, including bisphosphonates or stem cell transplant preparatory drugs, can challenge renal clearance.

Agents frequently linked to nephrotoxicity include cisplatin, high-dose methotrexate, ifosfamide, and certain targeted therapies or immune checkpoint inhibitors. To prevent damage, clinical teams administer vigorous intravenous hydration before and after drug infusions, adjust dosages based on kidney clearance rates, and avoid concurrent use of other kidney-stressing drugs. If injury occurs, treatment may be paused or modified until renal markers stabilise.